Lesaffre has acquired a majority interest in Envera, a bioscience-based company based in West Chester, Penn. Financial terms of the transaction were not disclosed.

Founded in 2004, Envera develops microbial- and enzyme-based products for the consumer, institutional, agricultural, wastewater and bioremediation markets. Envera’s technology platform includes expertise in the areas of bacteriology, mycology, enzymology, and chemistry.

The addition of Envera will enhance Lesaffre’s presence and product offering in the nutritional ingredients and health sector, the company said.




“Envera’s impressive range of bacteria strains and products will enable us to widen our offering of microorganisms to our customers, especially in the field of human, animal and plant care activity,” said Paolo Rossi, president of Lesaffre’s nutrition and health segment. “What’s unique about Envera is its experience in the isolation, selection, production and formulation of microbial cultures.”

This transaction is the second biotechnology investment Lesaffre has made within the past year. In July, the company invested in Intralytix, another U.S. biotechnology company.

Antoine Baule, Lesaffre
Antoine Baule, c.e.o. of Lesaffre
“Lesaffre welcomes this acquisition, which is entirely in line with its strategic development objectives,” said Antoine Baule, chief executive officer of Lesaffre. “We are pleased to contribute to Envera’s development and to build upon the skills and expertise of the team in place. The specific technology and the strains collection developed by the company will provide a substantial addition to our current portfolio.”